Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 11;10(9):666. doi: 10.1038/s41419-019-1871-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a Schematic representation of NFYC (miR-30c host gene) and putative p53 binding sites in intron 5 of NFYC. b HEK-293T cells were treated with pcDNA3.1-p53 (wtp53), pcDNA3.1-p53R280K (mutp53), ADR (0.5 µM), pifithrin-α (10 µM), pifithrin-α + ADR or the miR-30c promoter constructs (in the pGL3 vector). Relative luciferase activity was assayed. **p < 0.01 vs. PGL3 vector, ^##p < 0.01 vs. pifithrin-α group. c ChIP assay showing endogenous p53 bound to the miR-30c promoter in the p53 binding site region in MCF-7 cells. d MCF-7 and MDA-MB-231 cells were treated with ADR (0.5 µM) for 12, 24, and 48 h. The expression of mature miR-30c and pri-miR-30c was evaluated by qRT-PCR. The protein expression of p-p53, p53, and p21 was examined by Western blotting. *p < 0.05, **p < 0.01 vs. 0 h group. e MCF-7 and MDA-MB-231 cells were treated with control, p53shRNA, ADR, or p53shRNA + ADR for 48 h. qRT-PCR showed that the miR-30c expression changes. The protein expression of p53 was examined by Western blotting. f MCF-7 and MDA-MB-231 cells were transfected with NC inhibitor (20 nM) or miR-30c inhibitor (20 nM) and were then treated with ADR and p53cDNA. The expression of FANCF and REV1 was analyzed by Western blotting. MCF-7 cells: *p < 0.05, **p < 0.01 vs. Blank group; ^#p < 0.05 vs. ADR group, ^##p < 0.01, vs. p53cDNA group. MDA-MD-231 cells: *p < 0.05 vs. Blank group; ^#p < 0.05 vs. p53cDNA group. g FANCF and REV1 expression in MCF-7 and MDA-MB-231 cells transfected with p53 shRNA, miR-30c mimic (miR-30c) or the negative control (NC). The expression of FANCF and REV1 was analyzed by Western blotting. **p < 0.01, ***p < 0.001 vs. Blank group; ^#p < 0.05 vs. Blank group. h qRT-PCR analysis of miR-30c expression in ADR-treated MCF-7 and MDA-MB-231 xenografts. Western blot analysis of p-p53, p53, FANCF, and REV1 expression in ADR-treated MCF-7 and MDA-MB-231 xenografts. **p < 0.01, ***p < 0.001 vs. Blank group. NS indicates no significant difference. Data represent the mean ± SD (n = 3, each group)